RET inhibitors

News

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.

News

New era of genomic medicine begins as UK approves Lilly's Re...

The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung cancers and thyroid cancers, which the company said could herald a new er

News

J&J scores EU approval for Tecvayli combo in second line

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks